Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2021	Mar. 31, 2021
Current assets:
Cash and cash equivalents	$ 484,960,000	$ 674,493,000
Accounts receivable, net	10,608,000	3,570,000
Marketable securities	84,826,000	10,435,000
Inventory	4,172,000	2,611,000
Milestone receivable from Pfizer	100,000,000	0
Prepaid expenses and other current assets	17,569,000	13,536,000
Total current assets	702,135,000	704,645,000
Property and equipment, net	2,968,000	3,300,000
Operating lease right-of-use asset	9,252,000	9,655,000
Other assets	13,415,000	7,427,000
Total assets	727,770,000	725,027,000
Current liabilities:
Accounts payable	9,122,000	17,809,000
Accrued expenses and other current liabilities	42,938,000	44,612,000
Share-based compensation liabilities	21,151,000	21,636,000
Deferred revenue	117,231,000	100,564,000
Amounts due to Pfizer	11,025,000	1,954,000
Cost share advance from Pfizer	104,178,000	92,415,000
Operating lease liability	1,886,000	1,807,000
Amounts due to related parties	39,000	543,000
Total current liabilities	307,570,000	281,340,000
Deferred revenue, non-current	451,193,000	397,369,000
Cost share advance from Pfizer, non-current	0	29,447,000
Long-term operating lease liability	8,685,000	9,189,000
Long-term debt, less current maturities (related party)	358,700,000	358,700,000
Other liabilities	1,248,000	2,947,000
Total liabilities	1,127,396,000	1,078,992,000
Commitments and contingencies (Note 9)
Shareholders’ deficit:
Common shares, par value $0.000017727 per share, 564,111,242 shares authorized, 91,942,643 and 91,000,869 issued and outstanding at June 30, 2021 and March 31, 2021, respectively	2,000	2,000
Additional paid-in capital	725,465,000	709,466,000
Accumulated other comprehensive loss	(17,285,000)	(17,285,000)
Accumulated deficit	(1,107,808,000)	(1,046,148,000)
Total shareholders’ deficit	(399,626,000)	(353,965,000)
Total liabilities and shareholders’ deficit	$ 727,770,000	$ 725,027,000